Plasma resistin levels associate with risk for hypertension among nondiabetic women.
Emerging evidence suggests a role for resistin in inflammation and vascular dysfunction, which may contribute to the pathogenesis of hypertension, but the association between resistin levels and incident hypertension is unknown. We examined the association between plasma resistin levels and the risk for incident hypertension among 872 women without a history of hypertension or diabetes from the Nurses' Health Study. We identified 361 incident cases of hypertension during 14 years of follow-up. After adjustment for potential confounders, resistin levels in the highest tertile conferred a 75% higher risk for hypertension than the lowest tertile (relative risk [RR] 1.75; 95% confidence interval [CI] 1.19 to 2.56). Further adjustment for other adipokines did not change the RR substantially. In stratified analysis, resistin levels in the highest tertile significantly increased the risk for hypertension among women aged >or=55 years (adjusted RR 2.40; 95% CI 1.55 to 3.73) but not among women aged <55 years (adjusted RR 0.64; 95% CI 0.25 to 1.62). In a subset analysis of 362 women who also had measurements of inflammatory and endothelial biomarkers, plasma resistin levels significantly correlated with IL-6, soluble TNF receptor 2, intercellular adhesion molecule 1, vascular adhesion molecule 1, and E-selectin after controlling for age and body mass index. After further adjustment for these biomarkers and C-reactive protein, resistin levels remained significantly associated with incident hypertension. In conclusion, higher plasma resistin levels independently associate with an increased risk for incident hypertension among women without diabetes.
Zhang
Luxia
L
Channing Laboratory, Department of Medicine, Renal Division, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts 02115, USA. nhlzh@channing.harvard.edu
Curhan
Gary C
GC
Forman
John P
JP
D006631:Amine Oxidase (Copper-Containing) / Q000097:blood; D015415:Biomarkers / Q000097:blood; D002097:C-Reactive Protein / Q000378:metabolism; D016022:Case-Control Studies; D015815:Cell Adhesion Molecules / Q000097:blood; D019040:E-Selectin / Q000097:blood; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D006973:Hypertension / Q000097:blood* / Q000453:epidemiology* / Q000503:physiopathology; D015994:Incidence; D018799:Intercellular Adhesion Molecule-1 / Q000097:blood; D015850:Interleukin-6 / Q000097:blood; D008875:Middle Aged; D011446:Prospective Studies; D018124:Receptors, Tumor Necrosis Factor / Q000097:blood; D052243:Resistin / Q000097:blood*; D012189:Retrospective Studies; D012307:Risk Factors
D015415:Biomarkers; D015815:Cell Adhesion Molecules; D019040:E-Selectin; D015850:Interleukin-6; D018124:Receptors, Tumor Necrosis Factor; D052243:Resistin; D018799:Intercellular Adhesion Molecule-1; D002097:C-Reactive Protein; C076668:AOC3 protein, human; D006631:Amine Oxidase (Copper-Containing)